News

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...
Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...
BrainStorm gets US FDA nod to begin phase 3b trial of NurOwn to treat amyotrophic lateral sclerosis: New York Wednesday, May 21, 2025, 18:00 Hrs [IST] BrainStorm Cell Therapeutics ...
Stem cells sound vaguely futuristic but they are increasingly being used in a wide range of medical applications. Their ...
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative ...
NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem ...
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...
New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa ...
Forthcoming press releases will feature additional notable oral abstracts. More information on all MD Anderson ASCO Annual ...